baber/WOPTO huggingface dataset:
Patent NZ-512440-A (NZ)
Title: Coating composition containing polyol prepared by reacting together polyhydroxy-tertiary amine with organic polyisocyanate
Inventor: HUYNH-BA GIA
IPC: B05D7/14
Filed: 2001-06-18
Abstract: Polyol prepared by reacting together polyhydroxy-tertiary amine with organic polyisocyanate, the polyhydroxyl-tertiary amine having at least one tertiary amine nitrogen atom and at least two hydroxyl groups being bonded indirectly to a nitrogen atom of the amine through a chain containing at least two carbon atoms, essentially all of the isocyanate groups of the organic polyisocyanate being reacted with hydroxyl groups of the amine, and a coating composition containing a film forming binder and a volatile organic liquid carrier, where the binder contains (I) hydroxyl-containing acrylic polymer and (II) the polyol as described herein above.
Patent NZ-513269-A (NZ)
Title: Pulley for double hung windows
Inventor: EVANS GARY
IPC: B66D3/04
Filed: 2001-08-01
Abstract: A pulley apparatus (27) is provided for use with double hung vertical sash windows, comprising a base (32) and a pair of pulleys (42) each having an axle (41) supported by the base.  The base has a pair of ears (43) that extend away from the pulleys and a pair of cord openings (53) with each opening in registry with an outer extremity (60) of one of the pulleys.  The base optionally includes a yoke (40), which supports at least one of the axles, and is vertically adjustable with respect to the base.  The apparatus is adapted to be installed into a recess in a window head (20) so that it is flush with the head.
Patent NZ-513760-A (NZ)
Title: Tapered corrosion protection of tubes at mud drum location
Inventor: HARTH GEORGE H III
IPC: F22B37/04
Filed: 2001-08-24
Abstract: Described is a method of corrosion protecting a tube having an end portion extending into a tube-receiving hole of a mud drum of a boiler and the tube produced by that method.  The end portion of the tube is provided with a corrosion-resistant cladding layer that may contain chromium.  Laser cladding is used to produce the corrosion resistant cladding layer, which advantageously tapers along a length of the end portion of the tube.  The tube may be swaged before or after the cladding is applied and suitable heat treatments may be performed on the bare or clad tube to develop suitable properties in the tube; the cladding, or a tube-cladding interface. A schematic sectional view of the laser cladding applied to an area of a mud drum tube, which is particularly susceptible to corrosion, is depicted.
Patent NZ-514436-A (NZ)
Title: System and method for broadband millimeter wave data communication
Inventor: FOSTER ROBERT B
IPC: H04W72/12
Filed: 1997-09-22
Abstract: Broadband information communication is provided between a plurality of processor-based systems by a first communication node coupled to a first processor-based system and a second node coupled to a second processor-based system.  These first and second nodes (Fig 4) each incorporate an antenna 410, a radio frequency modem 440, a communication module 430 coupled between the modem and the antenna, and a controller unit 450 including a processor 460 coupled to an electronic memory 470 and the modem and an interface 480 adapted for coupling to the processor based system.  The node antennae are adapted to receive radio frequency communications in the milli-metric band (1.4GHz to 38GHz).  A communication hub 101 provides information communication between the first and second nodes and to this purpose includes a plurality of antenna elements 200a, 200b each of which is adapted to receive the radio frequency communication from a node and each of which is coupled to a hub communication module 250. The hub includes a radio frequency modem 240 that is switchably coupled to the hub communication modules of the hub antenna elements via a first switch 230 and a controller unit 250 including a processor 260 that is coupled to a memory 270, the switch 230 and the hub modem 240.
Patent NZ-517647-A (NZ)
Title: Bacterial consortium EBC1000 and a method using the bacterial consortium EBC1000 for remedying biologically recalcitrant toxic chemicals contained in industrial wastewater, waste materials and soils
Inventor: LEE SUNG-GIE
IPC: C12R1/22
Filed: 2000-07-11
Abstract: A bacterial consortium EBC1000 (KCTC 0652 BP) and a method for remedying biologically a chlorine compound and recalcitrant toxic chemicals contained in industrial wastewater, waste materials and soils using the bacterial consortium EBC1000. The bacterial consortium EBC1000(KCTC 0652 BP) is composed of aerobic bacterium easy to culture and useful for decomposing a chlorine compound and waste acidic or alkaline recalcitrant toxic chemicals of high concentration contained in the industrial waste materials, such as IPA, MC, DMA, AN, SHS, BD, Tamol-SN, EDTA, FES, TDDM, PMH, DEHA, MeOH, NaOH and CH3CN, thus preventing and recovering environmental pollutions.
Patent NZ-519595-A (NZ)
Title: 3-Substituted 4-phenyl-piperazine or piperidine derivatives useful as modulators of dopamine neurotransmission
Inventor: SONESSON CLAS
IPC: C07D295/073
Filed: 2000-12-22
Abstract: A 3-substitued 4-(phenyl-N-alkyl)-piperidine compound of formula 1 is described wherein: R1 is selected from CF3, CN, F, Cl, Br, I, OSO2CF3, OSO2CH3, SOR3, SO2R3, COCH3, COCH2CH3, COCH(CH3)2, NO2, CONHCH3 and CONHCH2CH3 R2 is selected from C1-C4 branched or unbranched alkyls, terminal allyls, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluropropyl and 4,4,4-triflurobutyl R3 is selected from C1-C3 alkyls, CF3 and N(R2)2 wherein the compound does not have a high binding affinity to sigma receptors. Pharmaceutical compositions comprising the compound are useful for the treatment of a disorder in the central nervous system, a dopamine mediated disorder, movement disorders, tics, tremors, Tourette's disease, stuttering and other speech disorders, iatrogenic and non-iatrogenic Parkinsonism, dyskinesias and dystonias, iatrogenic and non-iatrogenic psychoses, hallucinoses, schizophrenia and schizophreniform disorders , mood and anxiety disorders, mono depressive illness, depression and obsessive-compulsive disease, neurodevelopmental and age related disorders and cognitive dysfunction such as attention-deficit disorders, autism disorders, bradykniesia and bradyphrenia, sleep disorders, sexual disorders, eating disorder, obestias, headaches, pain, substance related disorders, for the improvement of motor function, cognitive function and related emotional disturbances in neurodegenerative and developmental disorders and after brain injury induced by traumatic, toxic, inflammatory, infectious, neoplastic, vascular hypoxic or metabolic causes.
Patent NZ-521435-A (NZ)
Title: Timing device
Inventor: PALMER MICHAEL BRETT
IPC: F02M65/00
Filed: 2002-09-16
Abstract: A timing device comprising a first member including a fuel chamber, an inlet to said fuel chamber adapted for 5 connection with a diesel fuel line, and an outlet from said fuel chamber, a valve member biased to close off said outlet and adapted to open said outlet under increased fuel pressure in said chamber; a valve member movement detector, detecting an opening movement of said valve member and providing an output indicating opening of said valve member, a collection reservoir fitted over said outlet to receive and collect fuel ejected through said outlet; and a strobe lighting arrangement receiving said output from said valve member movement detector and providing a light pulse synchronised with an immediate response to each valve member opening event.
Patent NZ-522395-A (NZ)
Title: Network based KVM switching system using a converter between a server and a workstation
Inventor: THOMAS CHRISTOPHER L
IPC: G06F3/038
Filed: 2000-06-21
Abstract: A converter providing an alternative data path between a selected server (41) on a packet switched network and a workstation (51) on the same packet switched network, the server (41) communicating with the workstation via a corresponding network interface, the converter (47) comprises: a motherboard access link communicating with a motherboard (42) of the server (41), the motherboard access link is different from the network interface; a network link, different from the motherboard access link, providing access to the workstation through the same packet switched network; and a data converter (47) to bi-directionally communicate data to and from the server and the workstation, without routing through the network interface of the server, by: 1) retrieving incoming data from the packet switched network addressed to the converter (47), and applying the incoming data to the motherboard access link according to a device protocol suited for the server (41), and 2) sending outgoing data from the server (41) to the packet switched network by addressing it to the workstation (51) according to a packet switched network protocol.
Patent NZ-522411-A (NZ)
Title: Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
Inventor: DVORAK CHARLES ALOIS
IPC: C07D417/06
Filed: 2001-05-16
Abstract: Compounds of formula (I) which are generally muscarinic M2/M3 receptor antagonists are disclosed, wherein: one of X, Y or Z is independently -S-, -0-, -CH2- or >N-R6, the others are -CH2-; m is an integer from 0 to 3 inclusive; n is an integer from 1 to 6 inclusive; R4 is (C1-6)-alkyl; R5 is (C1-6)-alkyl, (C2-6)-alkenyl, (C2-6)- alkynyl or cycloalkyl; and R1, R2, R3 and R6 are hydrogen or specified substituents as defined in the specification. These compounds are useful for treating diseases associated with smooth muscle disorders.
Patent NZ-527565-A (NZ)
Title: Methods and devices for tissue repair
Inventor: WERKMEISTER JEROME ANTHONY
IPC: A61L27/38
Filed: 2002-02-04
Abstract: Use of cells, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles in the preparation of a composition comprising a gel and/or gel-forming substance for treating diseased or damaged tissue in a subject are disclosed, wherein the cells and/or suitable progenitor cells are of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and wherein the composition is for administration to the subject at a site wherein the diseased or damaged tissue occurs. Where the cells and/or suitable progenitor cells thereof are chondrocytes, embryonic stem cells and/or bone marrow stromal cells, the methods of the invention are suitable for treating, for example, articular cartilage degeneration associated with primary osteoarthritis. Also disclosed is a device having tissue-like characteristics for treating diseased or damaged tissue in a subject, wherein the device comprises cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with bioresorbable beads or particles and optionally a gel and/or gel-forming substance.
Patent NZ-527650-A (NZ)
Title: Preservative blends containing quaternary ammonium compounds
Inventor: LUTZ PATRICK JAY
IPC: A01N39/00
Filed: 2002-02-28
Abstract: Disclosed herein is a preservative formulation comprising a synergistic mixture of: (a) a benzethonium salt; and (b) at least one of: (i) dehydroacetic acid or a salt thereof; and (ii) salicylic acid or a salt thereof. The preservative formulation may further comprise: (c) benzoic acid or a salt thereof; (d) phenoxyethanol; and (e) benzyl alcohol.
Patent NZ-530042-A (NZ)
Title: A pharmaceutical formulation comprising an antibiotic that has good bioavailability wherein the bad taste is masked
Inventor: BECOURT PHILIPPE
IPC: A61P31/04
Filed: 2002-06-21
Abstract: Described is a pharmaceutical formulation in the form of a powder, which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state in an atomized matrix. In addition to an alkaline agent and an adsorbing agent, a method for the production thereof and a method for masking the taste of pharmaceutical products are described also.
Patent NZ-531665-A (NZ)
Title: PRO1558 polypeptides and sequences thereof with homology to methyltransferase enzymes
Inventor: BAKER KEVIN
IPC: A61K39/395
Filed: 1999-09-01
Abstract: An isolated nucleic acid having at least 80% sequence identity to a nucleotide sequence that encodes a polypeptide designated PRO1558 comprising the amino acid sequence SEQ ID NO:306 is described. Preferably the nucleic acid comprises the sequence of SEQ ID NO:305 or is that deposited under accession number ATCC 203312. Vectors, isolated host cells, processes for preparing the polypeptide, pharmaceutical compositions and antibodies are also described. (62) Divided out of 510464
Patent NZ-534066-A (NZ)
Title: Preservation of vegetables and herbs containing one water soluble organic acid salt
Inventor: FROELICH MARKUS
IPC: A23L27/10
Filed: 2002-12-18
Abstract: A shelf stable non-dried vegetable preparation containing one water soluble organic acid salt that reduces the water activity to a value below or equal 0.65 and increases the pH to a value of 6.5 to 7.5 ambient conditions, wherein the organic acid salt is selected from the group comprising acetate salts, ascorbate salts, aspartate salts, citrate salts, fumarate salts, malate salts, tartrate salts, succinate salts and lactate salts.
Patent NZ-535323-A (NZ)
Title: Bipolar trans carotenoid salts and their uses
Inventor: GAINER JOHN L
IPC: A61P25/28
Filed: 2003-02-25
Abstract: Disclosed are trans carotenoid salt compounds and methods of making them. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.
Patent NZ-537683-A (NZ)
Title: Methods and systems for effecting payment card transactions
Inventor: BARRY GERARD J
IPC: G06Q20/00
Filed: 2003-07-14
Abstract: A system adapted to effect the performance of a payment card transaction comprises: means for receiving details of a transaction for a first transaction amount in a first currency, between a first merchant and a first payment card holder, means for creating a first payment card transaction record between the first merchant and a second cardholder for the first transaction amount; means for creating a second payment card transaction record between a second merchant and the first cardholder, and means for submitting created transaction records to a host for processing as payment card transactions. The second transaction record identifies a second transaction amount in a second currency which equates to the first transaction amount converted into the second currency.
Patent NZ-547880-A (NZ)
Title: Solid pharmaceutical preparation form
Inventor: BRAUNS ULRICH
IPC: A61K31/46
Filed: 2004-11-10
Abstract: Disclosed is a solid pharmaceutical preparation form containing one or more solid carriers and/or excipients and an active substance selected from among the Monoamine Neurotransmitter Re-uptake Inhibitors which have a 2,3-disubstituted tropane structure, obtained by spraying a solution of this active substance onto at least one carrier.
Patent NZ-550869-A (NZ)
Title: A coupler with latch for twin pin digger bucket
Inventor: SCHIEB MICHAEL KEVIN
Filed: 2006-10-26
Abstract: A coupler assembly to interpose between the arm of the vehicle and a parallel pinned implement having two docks, one on each of the two members able to be caused to slide relative to each other, each dock engageable outwardly to its pin with at least one pin being captive in its dock by a pivoted retention member.
Patent NZ-564364-A (NZ)
Title: Process for producing a mineral whey product
Inventor: PHILLIPS MICHAEL JOHN
IPC: A23L33/00
Filed: 2006-06-23
Abstract: Disclosed is a process for the production of a commercial mineral whey product derived from a feed stream of milk or whey, said process including the steps of: primary de-mineralisation of the feed stream by nanofiltration to produce a substantially de-proteinated and lactose-reduced high potassium stream and a protein and lactose rich demineralised stream; secondary demineralisation of the high potassium stream, either by precipitation and subsequent separation of a predominantly calcium-phosphate complex, or by the removal of calcium by ion exchange; concentrating the high potassium stream to obtain a mineral rich concentrate having a total solids content of around 20 to 60% by weight, wherein around 50% of said total solids is ash; and further processing of said concentrated said high potassium stream into a desired form for storage and distribution. Also disclosed is a mineral whey powder manufactured by the above process.
Patent NZ-565416-A (NZ)
Title: Therapeutic combination comprising a NMDA receptors blocker and a narcotic analgesic substance
Inventor: CHIESI PAOLO
IPC: A61K31/135
Filed: 2006-07-18
Abstract: Disclosed is a medicament comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof and a narcotic analgesic substance, wherein the two substances are administrated simultaneously. The medicament comprising the combination of said compound of formula (I) or a pharmaceutically acceptable salt thereof with a narcotic analgesic substance is suitable for the treatment of a subject suffering from a moderate to severe pain condition, acute or chronic, whether the pain is of neuropathic or inflammatory type or caused by different nociceptive stimuli.
Patent NZ-565563-A (NZ)
Title: Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
Inventor: HORVATH PHILIPPE
IPC: C12N15/74
Filed: 2006-08-25
Abstract: Disclosed is the use of one or more cas (Clustered Regularly Interspaced Short Palindromic Repeat [CRSPR]-associated) genes or proteins for modulating resistance in a bacterial cell against a target nucleic acid or a transcription product thereof. Further disclosed are methods of modulating the resistance of a bacterial cell with said cas genes.
Patent NZ-566034-A (NZ)
Title: Method for detection of microorganism comprising treating a sample with an enzyme which decomposes non microorganism cell followed by treatment with a topoisomerase poison and/or a DNA gyrase poison
Inventor: YOSHIDA SHINICHI
IPC: C12Q1/04
Filed: 2006-02-17
Abstract: Disclosed is a method for preparing a measurement sample for detecting live cells of a microorganism in a test sample by flow cytometry, which comprises the following steps: a) the step of treating the test sample with an enzyme selected from lipolytic enzymes and proteases which having an activity of decomposing other than those of the microorganism, and colloidal particles of proteins or lipids existing in the test sample, and b) the step of treating the test sample with a topoisomerase poison selected from the group consisting of amsacrine, camptothecin, doxorubicin, ellipticine, etoposide, mitoxantrone, saintopin, topotecan, CP-115,953 and ethidium monoazide and/or a DNA gyrase poison selected from the group consisting of ciprofloxacin, ofloxacin, enoxacin, pefloxacin, fleroxacin, norfloxacin, nalidexic acid, oxolinic acid and piromidic acid. Further disclosed are methods for detecting live, injured and dead cell; and kits for preparing a measurement thereof.
Patent NZ-567629-A (NZ)
Title: Piperazine derivatives useful in the treatment of discorders of the central nervous system
Inventor: SUN CONNIE L
IPC: C07D295/08
Filed: 2006-09-18
Abstract: Disclosed herein are 1,4-piperazine derivatives of formula (I), wherein the substituents are as defined within the specification, processes for preparing said derivatives, intermediates useful in the process, pharmaceutical compositions comprising the derivatives and to the use of the derivatives in the treatment of a condition responsive to a modulator of sigma receptor function i.e. disorders of the central nervous system.
Patent NZ-571761-A (NZ)
Title: 5-phenylimidazoles
Inventor: THORMANN MICHAEL
IPC: C07D401/04
Filed: 2007-04-12
Abstract: Disclosed are compounds of formula (I), wherein R2 represents a group selected for the list consisting of -C1-6alkyINR10R11 and -C3-6cycloalkylimine optionally N substituted by R12; and the remaining substituents are as defined in the specification. The compounds are dipeptidyl peptidase IV (DP IV) inhibitors useful for the treatment of neurological diseases and neurodegenerative diseases such as anxiety, depression and Alzheimer's disease.
Patent NZ-572666-A (NZ)
Title: Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
Inventor: KOTELIANSKI VICTOR E
IPC: C12N15/113
Filed: 2007-05-10
Abstract: Disclosed is a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human proprotein convertase subtilisinlkexin type 9 (PCSK9) gene in a cell by targeting mRNA encoding PCSK9 from position 3530 to position 3548 of Accession No. NM_174936 (the sequence 5'UUCUAGACCUGUUUUGCUU-3') wherein the dsRNA comprises at least two sequences that are complementary to each other. Further disclosed are pharmaceutical compositions comprising said dsRNA that can be used for treating hypercholesterolemia, hypertriglyceridemia, hyperlipidemeia, heart disease or circulatory disease.
Patent NZ-574222-A (NZ)
Title: 2-(2-Oxoimidazolidin-1-yl)-thiazole-5-carboxamide derivatives and pharmaceutical uses thereof
Inventor: DALES NATALIE
IPC: C07D277/46
Filed: 2007-08-13
Abstract: Disclosed are 2-(2-oxoimidazolidin-1-yl)-thiazole-5-carboxamide derivatives as represented by the general formula (I), wherein: X is nitrogen; Y is sulfur; Q is a 2-oxoimidazolidin-1-yl group as represented by Q' or Q''; W is -N(R6)C(O)- or -R8-C(O)N(R6)-; V is a direct bond; R1 is halo, hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R1 is a multi-ring structure having 2 to 4 rings wherein the rings are independently cycloalkyl, heterocyclyl, aryl or heteroaryl and where some or all of the rings may be fused to each other; R2 is hydrogen, aryl, aralkyl, or heteroaryl; R3 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, halo, haloalkyl, haloalkoxyl, cyano, or -N(R6)2; and wherein the remaining substituents are as defined herein. Representative compounds include methyl 2-((3-(5-(benzylcarbamoyl)-4-methylthiazol-2-yl)-2-oxoimidazolidin-1-yl)methyl)benzoate; 2-(3-(isoquinolin-1-ylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide; and 2-(3-(4-fluorobenzyl)-2-oxoimidazolidin-1-yl)-4-methylthiazole-5-carboxamide. Further disclosed is a pharmaceutical composition which comprises a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier for treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, and for diseases or conditions such as metabolic syndrome, Syndrome X, diabetes, insulin resistance, decreased glucose tolerance, noninsulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, a diabetic complication, a body weight disorder, weight loss, a body mass index or leptin related disease, dyslipidemia, obesity, insulin resistance, hypertension, microalbuminemia, hyperuricaemia, or hypercoagulability or skin disorders such as eczema, acne, psoriasis, or keloid scar formation or prevention.
Patent NZ-578642-A (NZ)
Title: 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
Inventor: GUDE MARKUS
IPC: C07D513/04
Filed: 2007-12-28
Abstract: Disclosed are 2-aza-bicyclo[3.1.0]hexane compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein the substituents are as defined in the specification and their use as orexin receptor antagonists for treating diseases such as sleep disorders, stress-related disorders and cognitive dysfunction.